Cambrex Corporation (NYSE:CBM)
Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs) & advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics.
Cambrex Corporation (NYSE:CBM)’s Financial Overview
Cambrex Corporation (NYSE) surged 2.73% yesterday to close its trading session at $41.43. The company has 1 year Price Target of $62.8. Cambrex Corporation has 52-Week high of $69.43 and 52-Week Low of $35.98. The stock touched its 52-Week High on 69.43 and 52-Week Low on 35.98. The stock traded with the volume of 520140 shares yesterday. The firm shows the market capitalization of $1.41 Billion.
Cambrex Corporation (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.49/share against the analyst consensus estimate of $0.57/share. The difference between the actual and expected EPS is $-0.08 a share with a surprise factor of -14%.
The firm is trading with SMA20 of -2.86 Percent, SMA50 of -2.84 Percent and SMA200 of -21.09 percent. Cambrex Corporation has P/S value of 2.43 while its P/B value stands at 2.1. Similarly, the company has Return on Assets of 14.5 percent, Return on Equity of 21.7 percent and Return on Investment of 19.2 Percent. The company shows Gross Margin and Operating Margin of 39.2 percent and 23.7 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 1.2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 5 analysts offering 12-month price forecasts for Cambrex Corp have a median target of 63.00, with a high estimate of 71.00 and a low estimate of 57.00. The median estimate represents a +52.06% increase from the last price of 41.43.
Cambrex Corporation is expected* to report earnings on 02/13/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $1.32. The reported EPS for the same quarter last year was $1.27.
Pentair plc. (NYSE:PNR)
Pentair plc delivers industry-leading products, services and solutions for its customers’ diverse needs in water and other fluids, thermal management and equipment protection. It serves a range of industries, including Energy, Food & Beverage, Industrial, Infrastructure and Residential & Commercial. The Company is organized as three operating segments: Water & Fluid Solutions, Valves & Controls, and Technical Solutions. Pentair plc, formerly known as Pentair Ltd, is based in Dublin, Ireland.
Pentair plc. (NYSE:PNR)’s Financial Outlook
The 13 analysts offering 12-month price forecasts for Pentair plc have a median target of 44.00, with a high estimate of 52.00 and a low estimate of 38.00. The median estimate represents a +5.26% increase from the last price of 41.80.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
According to Zacks Investment Research, Pentair plc. has a Consensus Recommendation of 2.62. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 1.73% and closed its last trading session at $41.8. The company has the market capitalization of $7.25 Billion. The stock has 52-week high of $49.07 and 52-Week low of $35.3. The firm touched its 52-Week high on 49.07 and 52-Week low on 35.30. The company has volume of 1.25 Million shares. The company has a total of 173.35 Million shares outstanding.
Pentair plc. (NYSE) in the last quarter reported its actual EPS of $0.6/share where the analyst estimated EPS was $0.59/share. The difference between the actual and Estimated EPS is $0.01. This shows a surprise factor of 1.7 percent.
The company has YTD performance of 10.64 percent. Beta for Pentair plc. stands at 1.23 while its ATR (average true range) is 0.8. The company has Weekly Volatility of 1.38%% and Monthly Volatility of 1.73%%.
Pentair plc. has distance from 20-day Simple Moving Average (SMA20) of 2.41%, Distance from 50-Day Simple Moving Average of 4.92 percent and Distance from 200-Day Simple Moving Average of -0.99%.
The Company currently has ROA (Return on Assets) of 7.2 percent, Return on Equity (ROE) of 13.6 Percent and Return on Investment (ROI) of 9.8% with Gross margin of 35.3 percent and Operating & Profit margin of 14.8% and 15.5% respectively.